An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...
10d
Zydus Wellness enters harvest phase in FY27 as ₹7,800-crore acquisition bet faces execution test
Zydus Wellness enters FY27 aiming for ₹5,700 crore revenue, focusing on growth post-₹7,800 crore acquisitions amid execution ...
AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin ...
Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for ...
Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.
Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA ...
From costs and recovery to fertility, age limits and success rates, eight leading fertility experts answer the biggest, most ...
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of ...
Hiya Kids Daily Growth + Protein. Available in a kid-approved Sweet Cream flavor, the clean, protein-based powder supports ...
Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets ...
Shattuck Labs pivots from oncology to autoimmune diseases after pipeline failure, now relying on early-stage asset SL-325 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results